See more : iFabric Corp. (IFABF) Income Statement Analysis – Financial Results
Complete financial analysis of Vaxxinity, Inc. (VAXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaxxinity, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ningbo Fuda Company Limited (600724.SS) Income Statement Analysis – Financial Results
- Flux Power Holdings, Inc. (FLUX) Income Statement Analysis – Financial Results
- Alliance Witan Ord (ALW.L) Income Statement Analysis – Financial Results
- Everdime Technologies, Inc. (RGST) Income Statement Analysis – Financial Results
- Nexus Industrial REIT (EFRTF) Income Statement Analysis – Financial Results
Vaxxinity, Inc. (VAXX)
About Vaxxinity, Inc.
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 66.00K | 557.00K | 0.00 |
| Cost of Revenue | 2.23M | 1.68M | 1.94M | 52.00K | 107.00K |
| Gross Profit | -2.23M | -1.68M | -1.87M | 505.00K | -107.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -2,834.85% | 90.66% | 0.00% |
| Research & Development | 33.67M | 47.63M | 71.38M | 20.57M | 10.66M |
| General & Administrative | 22.39M | 28.35M | 51.83M | 12.22M | 3.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.39M | 28.35M | 51.83M | 12.22M | 3.01M |
| Other Expenses | 0.00 | 0.00 | -8.37M | -5.76M | -27.00K |
| Operating Expenses | 56.05M | 75.98M | 123.20M | 32.79M | 13.66M |
| Cost & Expenses | 58.29M | 75.98M | 125.14M | 32.84M | 13.66M |
| Interest Income | 2.09M | 1.26M | 9.00K | 1.00K | 435.00K |
| Interest Expense | 696.00K | 514.00K | 840.00K | 1.18M | 435.00K |
| Depreciation & Amortization | 2.23K | 1.68M | 1.10M | 717.00K | 107.00K |
| EBITDA | -56.05K | -74.30M | -135.23M | -31.57M | -13.58M |
| EBITDA Ratio | 0.00% | 0.00% | -187,824.24% | -6,701.26% | 0.00% |
| Operating Income | -58.29M | -75.98M | -125.08M | -32.28M | -13.66M |
| Operating Income Ratio | 0.00% | 0.00% | -189,507.58% | -5,795.69% | 0.00% |
| Total Other Income/Expenses | 58.23M | 757.00K | -12.10M | -7.68M | -502.00K |
| Income Before Tax | -56.93K | -75.22M | -137.18M | -39.96M | -14.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | -207,840.91% | -7,173.61% | 0.00% |
| Income Tax Expense | -56.93K | -12.00K | 840.00K | -4.58M | 56.00K |
| Net Income | -56.93K | -75.21M | -138.02M | -35.38M | -14.22M |
| Net Income Ratio | 0.00% | 0.00% | -209,113.64% | -6,351.35% | 0.00% |
| EPS | -0.45 | -0.60 | -1.10 | -0.28 | -0.11 |
| EPS Diluted | -0.45 | -0.60 | -1.10 | -0.28 | -0.11 |
| Weighted Avg Shares Out | 126.51K | 125.94M | 125.39M | 125.45M | 125.45M |
| Weighted Avg Shares Out (Dil) | 126.51K | 125.94M | 125.39M | 125.45M | 125.45M |
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
The 5 Best and Worst Performing Small-Cap Stocks in January 2023
Why Shares of Vaxxinity Jumped This Week
Vaxxinity: Potential Strong Upsides Ahead
Why Shares of Vaxxinity Soared This Week
Why Did Vaxxinity (VAXX) Stock Gain 80% Today?
Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study
Source: https://incomestatements.info
Category: Stock Reports